



# Annual General Meeting of Shareholders for the Year 2026

Bioscience Animal Health Public Company Limited

Wednesday, April 22, 2026

at 9:30 a.m.

Via electronic media (E-AGM)

March 25, 2026

Subject Invitation to the 2026 Annual General Meeting (AGM) of Shareholders

To Shareholders of Bioscience Animal Health Public Company Limited

- Enclosures:
1. Copy of the Minutes of the 2025 Annual General Meeting of Shareholders (for Agenda 1).
  2. Annual Report 2025 Form 56-1 One Report (e-One Report) and Statement of financial position Statement of comprehensive income and cash flow statement ended 31 December 2025 in QR CODE format (for consideration of Agenda 2 and 3).
  3. Profiles of the nominated persons to be appointed as directors to replace those who retired by rotation (For the consideration of Agenda 5).
  4. List of independent directors, Proxies for attending the shareholders' meeting.
  5. Proxy Form A, Form B, and Form C as specified by the Department of Business Development set by the Ministry of Commerce (It is recommended to use Form B) for Proxy Form C (only in case of foreign investors who appoint a custodian in Thailand to be a share depository and custodian).
  6. Company's Articles of Association only in relation to the shareholders' meeting.
  7. Personal Data Protection Notice (Privacy Notice) is available via QR Code.
  8. Instructions and Procedures for Attending the Shareholders' Meeting via Electronic Media (E-Meeting)
  9. Acknowledgement Form for Participation in the Electronic Media (E-Meeting)

As Bioscience Animal Health Public Company Limited ("The Company") will hold the 2026 AGM of Shareholders on Wednesday, April 22, 2026 at 9:30 a.m. via Electronic Media (E-AGM).

**Agenda 1 To consider and certify the Minutes of the 2025 AGM of Shareholders**

**Facts and Reasons:** The Company held the Annual General Meeting of Shareholders for the year 2025 on April 23, 2025 and prepared the minutes of the meeting to be sent to relevant agencies. A copy of the minutes of the meeting is enclosed with the notice of this meeting. The details appear in **Enclosure No. 1**.

**The Board's Opinion:** The recording of the minutes of the meeting is accurate and complete according to the facts. Therefore, it is deemed appropriate to propose that the Annual General Meeting of Shareholders consider certifying the Minutes of the Annual General Meeting of Shareholders for the year 2025 dated April 23, 2025

**Voting:** This agenda item requires approval by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 2 To consider and acknowledge the Company's operating performance for the year 2025**

**Additional information:** The report on the Company's operating performance for the year 2025 appears in the Annual Report 2025 Form 56-1 One Report (e-One Report) in the form of a QR code (QR Code) that has been sent to the holder together with the notice of this meeting. (Details appear in Enclosure No. 2).

**Board's Opinion:** Agreed to propose to the Annual General Meeting of Shareholders to acknowledge the Board of Directors' report on the Company's operating results for the year 2025.

**Voting:** No voting is required for this agenda item as it is for acknowledgment only.

**Agenda 3 To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2025**

**Facts and Reasons:** According to the provisions of Section 112 of the Public Limited Companies Act B.E. 2535 has required the Board of Directors to provide the statements of financial position, the statements of comprehensive income and cash flows at the end of the company's fiscal year which has been audited by a certified public accountant and proposed to the shareholders' meeting at the annual general meeting to consider and approve.

In this regard, the company has prepared the statements of financial position, the statements of comprehensive income and cash flows for the period ending December 31, 2025, which has been audited by a certified auditor and has been reviewed by the Audit Committee As shown in the Annual Report 2025 Form 56-1 One Report (e-One Report) under the heading Financial Statements ended December 31, 2025 in the form QR Code (QR Code) (details appear in Enclosure No.2)

**The Board's Opinion:** It is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the Statement of Financial Position and Statement of Comprehensive Income for the period ended December 31, 2025 which has been audited by a certified auditor and reviewed by the Audit Committee. The key financial information is summarized as follows:

Description (Unit: Million Baht)	2025		2024	
	Consolidated	Separate	Consolidated	Separate
Total Assets	1,258	800	1,253	809
Total Liabilities	460	77	439	74
Revenue from Sales	2,254	462	2,324	488
Total Revenue	2,307	526	2,374	549
Net Profit for the Year	43	43	72	39
Earnings per Share (Baht/Share)	0.123	0.138	0.207	0.123

**Note:** Net profit for the year 2025 includes an allowance for slow-moving inventory amounting to Baht 47.59 million.

**Voting:** This agenda item requires approval by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2025**

**Facts and Reasons:** The Company has a policy to pay dividends depending on the performance of the business at the rate of not less than 30% of the net profit from the Company's consolidated financial statements and its subsidiaries and considered together with the separate financial statements. After deduction of corporate income tax and the allocation of all types of reserves. Legal reserves will be allocated at a rate of not less than 5% of the net profit from the separate financial statements.

**Opinion of the Board of Directors:** The Board of Directors deems it appropriate to proposed shareholders' meeting to consider and approve the profit apportionment and dividend payment from the company's operating results Y2025 as follows:

At present, the Company has allocated legal reserves of no less than 10 percent of the registered capital of 157.00 million baht, amounting to 15.70 million baht as required by law.

Due in the year 2025, The company has a net profit after income tax according to the consolidated financial statements amount of 42,759,088 baht, it was deemed appropriate to propose to the shareholders' meeting to approve the dividend payment to the shareholders. From the operating period from January 1, 2025 to December 31, 2025 in the form of cash at the rate of 0.12 baht per share, 314,000,000 shares, amounting to 37,680,000 baht, representing 88.12 percent of the net profit of the consolidated financial statements. The dividend payment rate is in accordance with the Company's dividend policy.

The Company has already paid an interim dividend on September 4, 2025 at the rate of 0.08 baht per share for 314,000,000 shares, totaling 25,120,000 baht. The remaining dividend payment from the second half six-month operating period 2025 at the rate of 0.04 baht per share, totaling 12,560,000 baht.

Determining the list of shareholders who are entitled to receive dividends (Record Date) on April 30, 2026 and dividend payment on May 18, 2026. However, the right to pay such dividends is still uncertain until it is approved by shareholders at the 2026 Annual General Meeting of Shareholders.

**Voting:** This agenda item requires approval by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation**

**Facts and Reasons:** According to Section 71 of the Public Limited Company Act B.E. 2535 and Article 19 of the Company's Articles of Association Including the Company's Board of Directors Charter Has stipulated that at every annual general meeting of shareholders one-third of the directors shall resign. If the number of directors cannot be divided exactly into three parts, the number of directors closest to one-third shall retire. The directors who retired by rotation may be re-elected. as detailed in Enclosure No. 3

At the Annual General Meeting of Shareholders for the year 2026, there are 3 directors who will retire by rotation are listed below,

- |                                   |                      |
|-----------------------------------|----------------------|
| 1. Mr. Dhanawat Khongjaroensombat | Director             |
| 2. Mr. Rajata Rajatanavin         | Independent Director |
| 3. Mr. Jade Donavanik             | Independent Director |

Between December 1, 2025, and December 31, 2025, the company announced on its website and notified through the electronic system of the Stock Exchange of Thailand to give shareholders the right to propose individuals they deem qualified according to the specified criteria to be considered for election as directors of the company. However, at the end of the specified period, no shareholders proposed any individuals for consideration as candidates for the company's board of directors.

**The Board's Opinion:** The Board of Directors, excluding interested directors, has carefully and prudently considered that the directors nominated for this term possess qualifications suitable for the company's business operations. In doing so, they have taken into account compliance with relevant criteria, experience, expertise, ethics and integrity, a transparent work history, and performance results. The company deems it appropriate to propose to the Annual General Meeting of Shareholders the reappointment of the 3 directors whose terms have expired for another term.

**Voting:** This agenda item requires approval by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 6 To consider and approve the directors' remuneration for the year 2026**

**Facts and Reasons:** The Board of Directors has considered the remuneration and a meeting allowance for company directors and sub-committees considering the suitability of the type of business company, business growth rate as well as the duties and responsibilities of the directors.

**Board's Opinion:** The Board of Directors considered and unanimously agreed to propose to the AGM of Shareholders to consider and approve the remuneration. which is the same rate as 2025, The details of the remuneration for the directors and sub-committees are as follows:

Monthly Remuneration for Directors

Position	Remuneration for Directors (baht per month)	
	2026	2025
Chairman of the Board	25,000	25,000
Director	20,000	20,000
Chairman of the Audit Committee	25,000	25,000
Audit Committee/Independent	20,000	20,000

Board meeting allowance

Position	Meeting allowance (baht per time)	
	2026	2025
Chairman of the Board	20,000	20,000
Director	15,000	15,000
Independent Director	15,000	15,000

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

Audit Committee and the Risk Management Committee meeting allowance

Position	Meeting allowance (baht per time)	
	2026	2025
Chairman of the Audit Committee	20,000	20,000
Audit Committee	15,000	15,000
Chairman of the Risk Management Committee	15,000	15,000
Risk Management Committee	10,000	10,000

**Other Benefits:** - None -

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

**Voting:** This agenda item shall be approved by a vote of not less than two-thirds of the shareholders present at the Meeting.

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2026**

**Facts and Reasons:** In order to comply with the Public Limited Companies, Act B.E. 2535, Section 120, The shareholders' meeting is required to appoint company's auditor and determine the auditor's remuneration every year. And according to the regulations of the Securities and Exchange Commission (SEC) requires companies that issue securities to which is a listed company on the Stock Exchange of Thailand must provide auditor rotation every 7-year accounting period.

**Opinion of the Board of Directors:** The Audit Committee has been considering the qualifications of auditors and audit fee that in Y2025, Baker Tilly Audit and Advisory Services (Thailand) Ltd. is an experienced auditor firm, which are famous and generally accepted. The Four of nominated auditors are not contrary to the SET, no relationship with, or any interest with the Company, Executives, major shareholders or any related persons, which may have an impact on performing tasks independently. The Board of Directors shall ensure that the Auditor can perform it tasks in time.

List of auditor name proposed by Baker Tilly Audit and Advisory Services (Thailand) Ltd.

Auditor	Certified Public Accountant registration number	Years of auditing the Company
Mr. Apichart Sayasit	4229	4 Years
Ms. Wimsri Jongudomsombat	3899	4 Years
Ms. Waleerat Akraisawat	4411	1 Year
Ms. Bunnarach Punnarach	6482	-

If the aforementioned auditors are unable to perform their duties, Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. procures other certified auditors of the firm auditing and expressing opinions on the Company's financial statements in place of such auditor.

In 2026, the audit fee will be settled at the total of 3,160,000 Baht per year which not include other expenses that are actually charged. Which decreased from the previous year by 300,000 Baht, or a percentage of 8.67% (In 2025, the audit fee was 3,460,000 Baht).

Comparison Table of Audit Fees for the Year 2025 - 2026

Audit Fee	2026	2025	Increased (Decreased)
The audit fee for the company's financial statements	1,335,000	1,335,000	-
The audit fee for the subsidiary's financial statements	1,825,000	2,125,000	(300,000)
<b>Total</b>	<b>3,160,000</b>	<b>3,460,000</b>	<b>(300,000)</b>

The Company and its subsidiaries Use the same auditing office “The committee will ensure that financial statements can be prepared in a timely manner.”

**Voting:** This agenda item requires approval by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 8 Consider other matters (if any)**

-

The Company has set the date for determining the names of shareholders who are entitled to attend the 2026 AGM of Shareholders (Record Date) on Friday, March 13, 2026. The Company has published this Notice of the 2026 AGM of Shareholders along with meeting documents and proxy form on the company's website [www.bis-group.com](http://www.bis-group.com) in the section "Shareholders' Meeting".

The Company hereby invites all shareholders to attend the Annual General Meeting of Shareholders for the year 2026, which will be conducted via electronic means (E-AGM) on Wednesday, 22 April 2026 at 9:30 a.m. The system will be available for access from 8:00 a.m. onwards. The live broadcast of the Meeting will commence only at the scheduled time. The Company will conduct the Meeting in accordance with its Articles of Association relating to shareholders' meetings and voting procedures, as detailed in **Enclosure No. 6**. In addition, guidelines for proxy appointment, registration, required documents for attending the Meeting, and voting procedures are provided in **Enclosures No. 8 and No. 9**, respectively.

The Company will open the registration system for shareholders to attend the Meeting from 8 April 2026 at 9:00 a.m. until the closing of the Meeting on 22 April 2026. Shareholders may register via the link provided by the Company, or through the website: <https://www.affinityrelation.com/service/>, or by scanning the QR Code. Shareholders or proxy holders who have successfully registered will receive a link for attending the Meeting via the email address specified in the registration form at least two (2) days prior to the Meeting date.

If any shareholder wishes to appoint another person to attend and vote on their behalf at the Meeting, please complete and sign the proxy form enclosed with this invitation (**Enclosure No. 5**). The Company

recommends the use of Proxy Form B, which allows shareholders to clearly specify their voting instructions. However, Proxy Form A (general form) and Proxy Form C (for foreign shareholders who appoint a custodian in Thailand to hold and safeguard their shares) are also enclosed for shareholders' consideration as appropriate.

In the event that a shareholder wishes to appoint an Independent Director of the Company as proxy, details of the designated Independent Directors are provided in **Enclosure No. 4**. Such Independent Directors have no special interest in any agenda item proposed at this Meeting, except for Agenda Item 6 regarding the consideration and approval of directors' remuneration for the year 2026.

To ensure that shareholders receive the maximum benefit from the Meeting and to fully protect their rights, the Company kindly requests that shareholders or proxy holders prepare all required supporting documents for registration in advance. In addition, should any shareholder have questions requiring clarification regarding the above agenda items, please submit such questions in advance by 17 April 2026, together with your name, address, telephone number, and email address (if any), to the following email address: [chanika.k@bis-group.com](mailto:chanika.k@bis-group.com)

Please be informed accordingly.

Yours sincerely,



(Mr. Vanchai Sriherunrusmee)

Chairman of the Board

**Bioscience Animal Health Public Company Limited**  
**Minutes of the 2025 Annual General Meeting of Shareholders**

Date, time and place

The meeting was held on April 23, 2025 at 14:00 p.m. at Jupiter Room 13, 1st Floor, Challenger Building, IMPACT Muang Thong Thani, Popular Road, Ban Mai Subdistrict, Pak Kret District, Nonthaburi Province.

Start a meeting

Mr. Vanchai Sriherunrusmee, Chairman of the Board, acted as the Chairman of the Meeting. The Chairman declared the 2025 Annual General Meeting of Shareholders open and assigned Mr. Rungroj Thavontanakul, Company Secretary and Ms. Natnicha Priewpanich, Master of Ceremonies, to conduct the meeting and present the agenda to the shareholders.

At the commencement of the 2025 Annual General Meeting of Shareholders, the following shareholders and proxy holders were present: 23 people came in person with a total of 82,492,680 shares and 12 proxies with a total of 127,118,102 shares, total shareholders was 35 proxies attended the meeting, totaling 209,610,782 shares, accounting for 66.76 percent of the total number of shares sold of the Company. The quorum was constituted according to the Company's Articles of Association, Chapter 5, Article 38.

In this regard, the meeting facilitator introduced the directors, executives, legal advisors and auditors attending the Company's meetings which consists of,

The company has 9 directors. All 9 directors attended the meeting, representing 100% of the total board. The attending directors were:

- |                                      |  |
|--------------------------------------|--|
| 1. Mr. Vanchai Sriherunrusmee        | Chairman of the Board,   |
| 2. Honorary Prof. Rajata Rajatanavin | Independent Director,<br>Chairman of the Audit Committee                                   |
| 3. Prof. Dr. Thaweesak Songserm      | Independent Director, Audit Committee<br>Chairman of the Risk Management Committee         |
| 4. Assoc. Prof. Dr. Jade Donovanik   | Independent Director, Audit Committee  |
| 5. Dr. Somjin Sornpaisarn            | Independent Director, Audit Committee  |
| 6. Mr. Dhanawat Khongjaroensombat    | Director, Chairman of Executive Board  |
| 7. Mr. Suchat Worrawutthangkool      | Director, Chief Executive Officer,<br>Risk Management Committee                            |
| 8. Mr. Poramase Kampak               | Director, Risk Management Committee  |
| 9. Mr. Rungroj Thavontanakul         | Director, Chief Administrative Officer,<br>Risk Management Committee,<br>Company Secretary |

Executives attending the meeting are as follows:

- |                              |                         |
|------------------------------|-------------------------|
| 1. Mr. Paphon Sirichotikul   | Chief Financial Officer |
| 2. Ms. Nareerat Chatkunakorn | Accounting Manager      |
| 3. Mr. Saran Chatiyanon,     | Executive Director      |

Legal Advisor from KPMG Phoomchai Audit Ltd.

- |                              |               |
|------------------------------|---------------|
| 1. Mr. Puchong Chairungreang | Legal Advisor |
|------------------------------|---------------|

Auditor from Baker Tilly Audit and Advisory Services (Thailand) Ltd.

- |                                |                             |
|--------------------------------|-----------------------------|
| 1. Mr. Apichart Sayasit        | Certified Public Accountant |
| 2. Ms. Wimolsri Jongudomsombut | Certified Public Accountant |
| 3. Ms. Bunnarach Punnarach     | Certified Public Accountant |

The Company had provided an opportunity for shareholders to propose matters for inclusion in the agenda of the AGM 2025 during on December 1-31, 2024. However, after the end of such period, none of the shareholders proposed any matter for inclusion in the agenda.

The Company recognizes the importance of the right to privacy and the protection of personal data. The Company processes personal data and records video footage for the purposes of the Annual General Meeting (AGM) and for public relations during the event. You may find details regarding the protection of personal data in the Privacy Notice located at the front of the meeting room.

To ensure the orderly conduct of the meeting, the meeting facilitators outlined the meeting procedures, voting guidelines, and the details of each agenda item. The Company engaged Affinity Relation Co., Ltd. to provide meeting services. Key points include:

1. Voting Procedures: Each attendee is entitled to vote in each agenda item based on the number of shares they hold or have been authorized to represent. One share equals one vote. Shareholders are not permitted to split their shares by assigning multiple proxies to vote differently. Shareholders must grant proxy authority for the entire number of shares they hold, except in the case of a custodian appointed by a foreign investor, as stipulated in Proxy Form C.
2. Proxy Voting - Form B: If a proxy has been assigned under Proxy Form B, and the shareholder has already specified their voting instructions, the proxy holder must vote accordingly. The system has already recorded these votes. The voting options available are: Agree, Disagree, or Abstain.
3. Vote Counting: The Company uses a barcode system for vote counting to ensure efficiency and accuracy.
4. Ballot Issuance at Registration Points: The registration staff will issue voting ballots in the following cases:
  - 1) Shareholders attending in person

- 2) Proxy holders using Form B or Form C, where the shareholder has granted authority to vote on specific agenda items
- 3) No ballot will be printed if the shareholder has already specified votes for each agenda item and authorized the proxy to vote accordingly. In such cases, the system will automatically record the votes.
- 4) Vote Counting Method: Only "Disagree" and "Abstain" votes will be counted. These will be deducted from the total votes of attendees, and the remainder will be deemed as votes in favor of the proposed resolution.

Therefore, shareholders wishing to vote "Disagree" or "Abstain" are kindly asked to raise their hands so that Company staff on either side may collect the ballots for tallying and submission to the Chairman to announce the results.

Please note that "Agree" votes will not be collected.

For ballot marking, please place an (X) in one box only— Agree, Disagree, or Abstain —and sign the ballot using a pen each time you vote.

5. Early Departure: If any shareholder or proxy wishes to leave before the meeting concludes and would like to vote on remaining agenda items, please sign and submit your completed ballots to the staff before exiting the meeting room. The Company will record your votes accordingly.
6. Vote Announcement: Voting results for each agenda item will be announced immediately after the vote count for that item is completed.
7. Tie Votes: In the event of a tie, the Chairman shall cast an additional vote to resolve the matter.

To ensure transparency and uphold good corporate governance, the Company invited an external legal representative Mr. Puchong Chairungreang, Legal Advisor from KPMG Phoomchai Audit Ltd. to witness the vote counting process.

#### **Agenda 1 To consider and certify the Minutes of the 2024 Annual General Meeting of Shareholders**

The Chairman proposed the minutes of the 2024 Annual General Meeting of Shareholders held on April 24, 2024 to the meeting for approval. A copy of the minutes of the meeting is enclosed with the notice of this meeting. The details appear in the document, Enclosure No. 1 which has been sent to all shareholders along with the meeting invitation letter.

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

Resolution of the meeting The meeting has considered in detail. It was found that the minutes of the 2024 Annual General Meeting of Shareholders were accurate and complete. Resolved to certify the minutes of the 2024 Annual General Meeting of Shareholders held on April 24, 2024 with the following votes:

Shareholder	Number (Votes)	Percentage
Agree	209,710,782	100.00
Disagree	0	0.00
Abstain	0	0.00
Bad card	0	0.00
<b>Total</b>	<b>209,710,782</b>	<b>100.00</b>

**Note:** 1. A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

2. In this agenda, there were 1 additional shareholders attending the meeting representing 100,000 shares (total of 36 attendees) totaling 209,710,782 shares in this agenda representing 66.78 percent of the total number of the company's issued and sold shares.

**Agenda 2 To consider and acknowledge the Company's operating results for the year 2024**

The chairman at the meeting assigned Mr. Suchat Worrawutthangkool, Chief Executive Officer of the Company mentioned an overview of the company's operating results for the year 2024 ended December 31, 2024

- **Performance in 2024:** As a result of strategies focusing on increasing the gross profit margin, the company achieved a net profit of THB 71.66 million, representing a 35.5% growth compared to 2023. Consequently, the net profit margin rose from 2.18% in 2023 to 3.02% in 2024.

- **International Market Expansion:** The company focused on expanding in international markets, particularly in Myanmar, Cambodia, and Vietnam. This led to an increase in the proportion of revenue from international markets from 5.8% in 2023 to 8.3% in 2024.

- **Infrastructure Development to Support Growth:** The company established infrastructure to support its expansion into the companion animal market, which continues to show strong growth potential. This included restructuring products and services in alignment with future direction, such as increased development of products under the company's own brand.

- **Expansion into Integrated Livestock and Large Feed Mill Customer Groups:** The company is committed to expanding this customer segment for sustainable business growth. As a result, this segment grew by 23% in 2024 and is expected to continue growing in the future.

Subsequently, Mr. Paphon Sirichotikul, Chief Financial Officer, presented the company's operating results for the year 2024 to the meeting.

The Company has revenue from sales for the year ended amounted to THB 2,323.61 million decreased by THB 88.79 million or 3.68% as compared to the previous year and its gross profit amounted to THB 345.74 million, representing a gross profit margin of 14.88% with a growth rate by 3.89% as compared to the previous year

Distribution Costs and administrative expenses for the year ended December 31, 2024 amounted to THB 290.72 million, increase by THB 11.69 million or 4.19% as compared to the previous year. The ratio of distribution costs and administrative expenses to total revenue for the year ended of 2024 and 2023 representing 12.25% and 11.50% respectively. Due to the company's expansion into a new business with an office in Myanmar, resulted to the increasing in operating expenses.

Net profit for the year ended December 31, 2024 and 2023 amounted to THB 71.66 million and THB 52.88 million respectively, representing a respective net profit margin of 3.02% and 2.18%. Net profit margin for the year ended of 2024 increased from the previous year. Mainly due to increasing in gross profit and profit from operations, as the result of the increased in net profit.

Total assets as of December 31, 2024 amounted to THB 1,252.60 million, increased by THB 24.51 million or 2.00% as compared to that at the end of previous year. The major assets are Cash and Cash Equivalents and Short-term Investments, trade and other receivables and inventories

Shareholders' equity as of December 31, 2024 amounted to THB 813.73 million, increased by THB 23.23 million or 2.94% as compared to that at the end of previous year. The Company's retain earning increasing during the year from operating income amounted to THB 71.66 million and dividend paid amounted to THB 37.68 million. In addition, the Company was increased the investment proportion from 51% to 84% of investment in a subsidiary which operate in pet business, resulting in a decrease in surplus from additional investment in subsidiaries.

Mr. Rungroj Thavontanakul, Company Secretary Clarified that the report on the Company's operating results for the year 2024 appears in the 2024 Annual Report Form 56-1 One Report (e-One Report) in the form of a QR code (QR Code) sent to shareholders together with invitation letter for this meeting (Details appear in the document Enclosure No. 2).

The company is committed to combating dishonesty and corruption. By specifying that the company includes all persons involved in conducting business in all departments. Follow the anti-fraud and corruption policy. and open channels for reporting clues or complaints along with guidelines for protection. In 2024, the company has implemented the policy. continuously for example, the company has posted an announcement. and disseminated through the intranet platform and the company's website. To communicate anti-corruption policies

and measures, including laws or other regulations related to such matters to directors, executives, and employees in order to create an understanding of anti-corruption policies. Guidelines and methods for reporting clues and complaints from ongoing illegal actions and there were no complaints from both internal and external parties.

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda.

*Mr. Ongart Thongpitaksakul, the authorized representative of the Thai Investor Promotion Association,* made the following suggestions:

1. To prepare a summary of performance in table format, showing key information such as revenue, profit, and assets in the invitation letter to the meeting, so that shareholders can clearly see an overview of the company's performance.
2. To include the voting results for each agenda item in the invitation letter for the annual shareholders' meeting, in line with good practices of publicly listed companies.
3. To commend the on-site shareholders' meeting format, as it allows for clear communication, especially when inquiries are made, providing straightforward and easy-to-understand answers.

*Mr. Vanchai Sriherunrusmee, Chairman of the Board,* explained that:

1. The company agrees with the shareholders' proposal to summarize the performance in a table format in the invitation letter to the meeting, in order to make the information easier to understand. The company has assigned the secretary to implement this in the following year.
2. Currently, the company displays the voting results on a screen during the meeting and will add this information to the invitation letter in the following year for greater completeness.
3. This year, the company is holding the meeting in an on-site format to provide shareholders the opportunity to ask questions and communicate clearly.

*Mr. Ongart Thongpitaksakul, the authorized representative of the Thai Investor Promotion Association,* asked the following questions:

1. The revenue proportion from the disease prevention and treatment products, dietary supplements, vitamins, and diagnostic products is about 15-25%. Does the company have any plans to adjust this revenue proportion, and does it consider the current revenue structure to be appropriate?
2. Does the company have plans to participate in the Thai Private Sector Collective Action Coalition Against Corruption (CAC)?

*Mr. Suchat Worrawutthangkool, the Chief Executive Officer,* explained that the company is focused on increasing profitability by emphasizing three main product groups Animal Health, Nutrition, Diagnostic. These three groups are key drivers of the company's revenue and profit, following the strategic direction set.

*Mr. Vanchai Sriherunrusmee, Chairman of the Board*, further explained that the company places particular importance on the Animal Health product group, which includes vaccines for animals. This is a product area in which the company has expertise and achieves high gross profit margins (GP). The company also focuses on animal disease diagnostic kits, especially the African Swine Fever diagnostic kit, which has generated significant revenue and profit since the company was listed on the stock exchange. Regarding participation in the CAC project, the company will assess the suitability and approach for involvement.

*Mr. Ongart Thongpitaksakul, the authorized representative of the Thai Investor Promotion Association*, raised the following questions based on the company's financial statements:

1. The overdraft (OD) amount of 43 million baht please provide details on the origin of this item.
2. The financial turnover ratios, including average collection period of 79 days, inventory turnover period of 48 days, and average payment period of 65 days are these levels appropriate for the industry, and are there any areas that need improvement?
3. The inventory balance at the end of 2023 was 911 million baht, while in 2024 it was 294 million baht a significant difference. Please provide further explanation regarding this change.

*Mr. Paphon Sirichotikul, Chief Financial Officer*, provided the following clarifications:

1. The overdraft (OD) mentioned is categorized as short-term borrowing. The company utilizes this credit facility to manage liquidity in accordance with the customer payment cycle.
2. The cash cycle and the collection period are considered appropriate. The company aims to grant suitable credit terms to customers and negotiate favorable trade credit conditions with suppliers to maximize benefit. Additionally, the company closely monitors and controls trade receivables and continuously tightens related policies.
3. The company's inventory balance at the end of 2024 was 264 million baht, down from 348 million baht at the end of 2023. This figure differs from the one cited in the shareholder's question.

*Mr. Vanchai Sriherunrusmee, Chairman of the Board*, provided the following additional explanations:

1. Overdrafts and short-term borrowings from financial institutions: In the separate financial statements, the amount is approximately 5 million baht in the form of promissory notes (P/N), utilizing bank credit facilities for cash flow management. It is common for companies to have credit lines with banks for internal working capital. In the consolidated financial statements, overdrafts from financial institutions amount to approximately 40 million baht. This is considered normal business practice and is used to support cash flow through overdraft facilities of five subsidiaries.

2. Accounts receivable turnover: In 2023, the average collection period was 70 days, which increased to 79 days in 2024 due to economic conditions and the impact of the pandemic. However, this remains within an acceptable range for the industry, which averages around 80 days. The company generally provides credit terms to customers ranging from 45 to 60 days.
3. Inventory: The decrease in inventory from the previous year was due to the absence of goods-in-transit at the end of 2024. In 2023, goods-in-transit amounted to approximately 70 million baht. This improvement in inventory management has helped enhance efficiency and reduce interest expenses.

When it appeared that there was no shareholder commenting and asking any additional questions, the meeting acknowledged the Company's operating results for the year 2024 ending December 31, 2024 as proposed and since it was an agenda for acknowledgment, no resolution required.

**Agenda 3 To consider and approve the statement of financial position statement of comprehensive income and cash flow statement which has been audited by the auditor for the year ended December 31, 2024**

The Chairman assigned Mr. Paphon Sirichotikul, Chief Financial Officer, to provide an explanation regarding this agenda item. The Company has prepared financial statements for the fiscal year ended December 31, 2024, which have been reviewed by the Audit Committee and has been audited and certified by the Company's certified auditor and proposed to the meeting for consideration. Statement of Comprehensive Income and cash flow statement ending December 31, 2024 as shown in the 2024 Annual Report Form 56-1 One Report (e-One Report). In the topic of financial statements for the period ended December 31, 2024 in the form of QR Code (Details appear in the document Enclosure No. 2) which has been sent to all shareholders together with the invitation letter.

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered Resolved to approve the statement of financial position, statement of comprehensive Income and cash flow statement of the Company for the accounting period ending December 31, 2024 with the following votes:

Shareholder	Number (Votes)	Percentage
Agree	239,710,782	100.00
Disagree	0	0.00
Abstain	0	0.00
Bad card	0	0.00
<b>Total</b>	<b>239,710,782</b>	<b>100.00</b>

**Note:** 1. A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

2. In this agenda, there was 1 additional shareholder attending the meeting representing 30,000,000 shares (total of 37 attendees) totaling 239,710,782 shares in this agenda representing 76.34 percent of the total number of the company's issued and sold shares.

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2024.**

The Chairman proposed that the meeting consider approving the dividend payment for the Company's operating results for the year 2024, and assigned Mr. Rungroj Thavontanakul, Company Secretary, to further explained to the meeting that the Company has policy to pay dividends depending on the performance of the business at the rate of not less than 30% of the net profit from the consolidated financial statements of the Company and its subsidiaries (Consolidated) and consider together with the separate financial statements. After deduction of corporate income tax and the allocation of all types of reserves. Legal reserves will be allocated at a rate of not less than 5% of the net profit from the separate financial statements.

Due in the year 2024, The company has a net profit after income tax according to the consolidated financial statements amount of 71,656,261 baht, it was deemed appropriate to propose to the shareholders' meeting to approve the dividend payment to the shareholders. From the operating period from January 1, 2024 to December 31, 2024 in the form of cash at the rate of 0.14 baht per share, 314,000,000 shares, amounting to 43,960,000 baht, representing 61.35 percent of the net profit of the consolidated financial statements. The Company has already paid an interim dividend on September 11, 2024 at the rate of 0.05 baht per share for 314,000,000 shares, totaling 15,700,000 baht. The remaining dividend payment from the second half six-month operating period 2024 at the rate of 0.09 baht per share, totaling 28,260,000 baht.

Determining the list of shareholders who are entitled to receive dividends (Record Date) on May 2, 2025 and dividend payment on May 20, 2025.

The meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered resolved to approve the allocation of legal reserves and dividend payment for the Company's performance For the accounting period ending December 31, 2024 with details as proposed with the following votes:

Shareholder	Number (Votes)	Percentage
Agree	239,710,782	100.00
Disagree	0	0.00
Abstain	0	0.00
Bad card	0	0.00
<b>Total</b>	<b>239,710,782</b>	<b>100.00</b>

**Note:** A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation.**

Mr. Vanchai Sriherunrusmee, Chairman of the Board, is a director due to retire by rotation. Therefore, Honorary Prof. Rajata Rajatanavin, Chairman of the Audit Committee, was invited to preside over the meeting in accordance with good corporate governance principles. The meeting chairman then invited the directors due to retire by rotation to leave the meeting room during the consideration.

The meeting facilitator further explained to the meeting that according to section 71 of the public company act B.E. 2535 and article 19 of the Company's articles of association including the board of directors' charter, every time One-third of the directors shall resign. If the number of directors cannot be divided exactly into three parts, the number of directors closest to one-third shall retire. Directors retiring by rotation may be re-elected.

At the 2025 Annual General Meeting of Shareholders, there are 4 directors who will retire by rotation. The profiles and information of the directors nominated for appointment this time appeared according to the document Attachment No. 3 that the Company has sent to all shareholders along with the meeting invitation letter. The Company with 4 directors who retired by rotation in 2025 as follows:

- |                                 |                       |
|---------------------------------|-----------------------|
| 1. Mr. Vanchai Sriherunrusmee   | Chairman of the Board |
| 2. Mr. Suchat Worrawutthangkool | Director              |
| 3. Mr. Rungroj Thavontanakul    | Director              |
| 4. Mr. Poramase Kampak          | Director              |

During the period from December 1, 2024 to December 31, 2024, the Company announced on its website and notified through the electronic system of the Stock Exchange of Thailand to grant shareholders the right to nominate qualified individuals, in accordance with the specified criteria, for consideration as candidates for directorship. However, at the end of the nomination period, no shareholders nominated any individuals for consideration as directors.

Then, the meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda.

*Mr. Ongart Thongphithaksakul, a shareholder rights volunteer and proxy from the Thai Investors Association*, inquired whether the Company has a policy regarding gender diversity in the appointment of directors and whether such a policy would be considered in the future.

*Honorary Prof. Rajata Rajatanavin, Chairman of the Audit Committee*, clarified that the Company does not restrict gender identity in the appointment of directors. Currently, director selection is based primarily on individual qualifications and suitability. Should there be any qualified candidates who are women or identify with other gender identities, the Company would be pleased to consider inviting them to join the Board in the future.

When it appeared that there was no shareholder commenting and asking any additional questions, Therefore, the meeting facilitator requested the meeting to proceed with the resolution on this agenda item.

**Resolution of the meeting** The meeting has considered in detail. It was unanimously resolved to approve the re-appointment of 4 directors who retired by rotation to serve as directors for another term with a majority vote of the shareholders who attended the meeting and voted as follows:

5.1 Mr. Vanchai Sriherunrusmee Chairman of the Board

Shareholder	Number (Votes)	Percentage
Agree	239,344,562	100.00
Disagree	0	0.00
<b>Total</b>	<b>239,344,562</b>	<b>100.00</b>
Abstain	366,220	-
Bad card	0	-

**Note:** The abstention vote belongs Mr. Vanchai Sriherunrusmee the amount of 366,220 shares, was not used as the basis for calculating the percentage.

5.2 Mr. Suchat Worrawutthangkool Director

Shareholder	Number (Votes)	Percentage
Agree	221,086,562	100.00
Disagree	0	0.00
<b>Total</b>	<b>211,086,562</b>	<b>100.00</b>
Abstain	18,624,220	-
Bad card	0	-

**Note:** The abstention vote belongs Mr. Suchat Worrawutthangkool the amount of 18,624,220 shares, was not used as the basis for calculating the percentage.

5.3 Mr. Rungroj Thavontanakul Director

Shareholder	Number (Votes)	Percentage
Agree	231,589,562	100.00
Disagree	0	0.00
<b>Total</b>	<b>231,589,562</b>	<b>100.00</b>
Abstain	8,121,220	-
Bad card	0	-

**Note:** The abstention vote belongs Mr. Rungroj Thavontanakul the amount of 8,121,220 shares, was not used as the basis for calculating the percentage.

5.4 Mr. Poramase Kampak Director

Shareholder	Number (Votes)	Percentage
Agree	221,592,262	100.00
Disagree	0	0.00
<b>Total</b>	<b>221,592,262</b>	<b>100.00</b>
Abstain	18,118,520	-
Bad card	0	-

**Note:** The abstention vote belongs Mr. Poramase Kampak the amount of 18,118,520 shares, was not used as the basis for calculating the percentage.

Agenda 6 To consider and approve the remuneration of directors for the year 2025.

The Chairman proposed that the meeting consider and unanimously agreed to propose to the AGM of Shareholders to consider and approve the remuneration, which is the same rate as 2024, Additionally, there will be an increase in the remuneration for the company's directors and the Risk Committee members for non-executive directors taking into account appropriateness, the Company's growth rate, as well as the duties and responsibilities of the directors Details are as follows:

Monthly Remuneration for Directors

Position	Remuneration for Directors (baht per month)	
	2025	2024
Chairman of the Board	25,000	25,000
Director	20,000	-
Chairman of the Audit Committee	25,000	25,000
Audit Committee/Independent	20,000	20,000

Board meeting allowance

Position	Meeting allowance (baht per time)	
	2025	2024
Chairman of the Board	20,000	20,000
Director	15,000	-
Independent Director	15,000	15,000

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

Audit Committee and the Risk Management Committee meeting allowance

Position	Meeting allowance (baht per time)	
	2025	2024
Chairman of the Audit Committee	20,000	20,000
Audit Committee	15,000	15,000
Chairman of the Risk Management Committee	15,000	15,000
Risk Management Committee	10,000	-

In this regard, the Board of Directors who are executives of the Company will not request monthly remuneration and meeting allowances for the Board of Directors

The moderator then gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered resolved to approve the remuneration, which is the same rate as 2024, Additionally, there will be an increase in the remuneration for the company's directors and the Risk Committee members for non-executive directors with details as proposed with the following votes:

Shareholder	Number (Votes)	Percentage
Agree	239,710,782	100.00
Disagree	0	0.00
Abstain	0	0.00
Bad card	0	0.00
<b>Total</b>	<b>239,710,782</b>	<b>100.00</b>

**Note:** A resolution on this agenda must be approved by a vote of not less than two-thirds of the shareholders attending the meeting.

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2024.**

The Chairman of the meeting assigned Mr. Paphon Sirichotikul, Chief Financial Officer, clarified to the meeting that in order to comply with the Public Limited Companies Act B.E. 2535, Section 120 which requires the shareholders' meeting to appoint and determine the auditor's remuneration every year and according to the regulations of the Office of the Securities and Exchange Commission (SEC) requiring companies that issue securities which is a listed company on the Stock Exchange of Thailand must arrange for auditor rotation every 7 year accounting period.

The Audit Committee has been considering the qualifications of auditors and audit fee that in Y2024, Baker Tilly Audit and Advisory Services (Thailand) Ltd. is an experienced auditor firm, which are famous and generally accepted. The three of nominated auditors are not contrary to the SET, no relationship with, or any interest with the Company, Executives, major shareholders or any related persons, which may have an impact on performing tasks independently. The Board of Directors shall ensure that the Auditor can perform it tasks in time

List of auditor name proposed by Baker Tilly Audit and Advisory Services (Thailand) Ltd.

Auditor	Certified Public Accountant registration number	Years of auditing the Company
Mr. Apichart Sayasit	4229	3 Years
Ms. Wimonstri Jongudomsombat	3899	3 Years
Ms. Waleerat Akraisawat	4411	-

In the event that the aforementioned auditor is unable to perform their duties, the company authorizes Baker Tilly Audit and Advisory Services (Thailand) Ltd. to provide another licensed auditor from their office to perform the audit and issue an opinion on the company's financial statements on behalf of the said auditor.

In 2025, the audit fee will be settled at the total of 3,460,000 Baht per year which not include other expenses that are actually charged. Which decreased from the previous year by 957,351 Baht, or a percentage of 21.67% (In 2024, the audit fee was 4,417,351 Baht).

Comparison Table of Audit Fees for the Year 2024 - 2025

Audit Fee	2025	2024	Increased (Decreased)
The audit fee for the company's financial statements	1,335,000	1,335,000	-
The audit fee for the subsidiary's financial statements	2,125,000	3,082,351	(957,351)
<b>Total</b>	<b>3,460,000</b>	<b>4,417,351</b>	<b>(957,351)</b>

Note : - In 2024 Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. was the auditor for the company and its subsidiaries in Thailand with an audit fee of 3,880,000 Baht and The Right Partner Consulting Group co., LTD was the auditor for the subsidiaries abroad with an audit fee of 537,351 Baht. The total audit fee amounts to 4,417,351 Baht  
- In 2025 Baker Tilly Audit and Advisory Services (Thailand) Co., Ltd. will be the auditor for the company and its subsidiaries both in Thailand and abroad, proposing an audit fee mounts to 3,460,000 Baht

The meeting facilitator gave the meeting an opportunity to express their opinions and ask questions related to this agenda. However, no shareholders expressed their opinions and asked questions. The moderator then asked the meeting to vote on this agenda.

**Resolution of the meeting** The meeting has considered Resolved to approve the appointment of the company's auditor. and determine the auditor's remuneration for the year 2025 with details as proposed. with the following votes

Shareholder	Number (Votes)	Percentage
Agree	239,710,782	100.00
Disagree	0	0.00
Abstain	0	0.00
Bad card	0	0.00
<b>Total</b>	<b>239,710,782</b>	<b>100.00</b>

**Note:** A resolution on this agenda must be approved by a majority vote of the shareholders who attend the meeting and vote.

**Agenda 8 Consider other matters (if any).**

The meeting facilitator explained to the meeting that the agenda proposed for consideration as specified by the Company in the notice of the 2025 Annual General Meeting of Shareholders had been considered and gave the opportunity to shareholders to express their opinions and asked questions about other matters in this agenda, with shareholders asking questions as follows:

*Mr. Ongart Thongpitaksakul, the shareholder rights volunteer and proxy of the Thai Investor Promotion Association, asked about the company's ESG (Environmental, Social, Governance) policies and practices.*

*Mr. Rungroj Thavontanakul, Company secretary, clarified that the company places significant importance on ESG operations. The company has established a dedicated team to oversee and take responsibility for these matters. Additionally, the company discloses information about its ESG policies and performance in the annual report (Form 56-1 One Report) and on the ESG Data platform through SET Link, in compliance with the Stock Exchange's requirements. This allows the company to present ESG information effectively and transparently. The company is committed to continuous development to ensure long-term business sustainability.*

As there were no shareholders expressing their opinions and asking any further questions, the Chairman thank all shareholders for taking their time to attend the meeting and declared the meeting adjourned at 15:15 p.m.

sign.....

(Mr. Rungroj Thavontanakul)

Company Secretary

sign.....

(Mr. Vanchai Sriherunrusmee)

Chairman of the meeting

QR code for download Annual Report 2025 Form 56-1 One Report (e-One Report) and Financial Statements Ended December 31, 2025



Using a QR Code (QR Code) for downloading the 2025 Annual Report Form 56-1 One Report (e-One Report) and financial statements for the year ended 31 December 2025

Shareholders can download information via QR Code (as shown in Enclosure No. 2) in accordance with the following steps.

**For iOS system (iOS 11 and above)**

1. Open the camera (Camera) on the phone.
2. Scan QR Code
3. The screen will have a message. (Notification) up to the top, press on that message.

Note: In case there is no message (Notification) on mobile phones, shareholders can scan the QR Code from other applications such as QR CODE READER, Facebook and Line etc.

**For Android system**

1. Open the application QR CODE READER, Facebook or Line.

Procedure for scanning QR Code via Line

- Enter the Line application and select Add friend (add friends).
- Select QR Code

2. Scan QR Code

## 1. Mr. Dhanawat Khongjaroensombat Age 55 Years



**Director**  
**Chairman of Executive Board**

### Shareholding Proportion (As of Dec 31, 2025)

- direct 8.89%
- indirect 8.00%

**Family relationship between executives: - None -**

**Duration of Directorship : 21 Years (1 March 2004 – Present)**

### Educational qualifications

- Bachelor's Degree in Veterinary Science, Kasetsart University

### Director training history

- Director Certification Program (DCP) Class 182, 2021
- Role of the Chairman Program Class 60/2025

### work experience

#### Listed Company (1 EA.)

- |                  |                             |   |
|------------------|-----------------------------|---|
| ● 2004 – Present | Director                    | Bioscience Animal Health Public Company Limited |
| ● 2024 – Present | Chairman of Executive Board | Bioscience Animal Health Public Company Limited |
| ● 2004 – 2023    | Chief Executive Officer     | Bioscience Animal Health Public Company Limited |

#### Other companies (9 EA.)

- |                  |                         |  |
|------------------|-------------------------|--|
| ● 2024 – Present | Director                | Pet Animal Data & Innovation Co., Ltd.           |
| ● 2023 – Present | Director                | Beyond Animal Science Co., Ltd.                  |
| ● 2017 – Present | Director                | BIS Group Holding Co., Ltd.                      |
| ● 2017 – Present | Director                | Qualified Essence Suppliers & Traders Co., Ltd.  |
| ● 2014 – Present | Chief Executive Officer | Pro Test Kit Co., Ltd.                           |
| ● 2012 – Present | Chief Executive Officer | Special Ingredient Services Co., Ltd.            |
| ● 2012 – Present | Chief Executive Officer | Pedex Co., Ltd.                                  |
| ● 2008 – Present | Chief Executive Officer | Nutrition Improvement Co., Ltd.                  |
| ● 2008 – Present | Chief Executive Officer | Feed and Ingredients Technological Hub Co., Ltd. |

<b>- Current position</b>	Director
<b>- History of attending the meeting in 2025</b>	Annual General Meeting of Shareholders 1/1 time Board of Directors 5/5 times Executive Committee 12/12 times
<b>- History of illegal acts in the past 10 years</b>	-None-
<b>- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET</b>	Yes
<b>- Direct or indirect interest in any business in which the company is a party.</b>	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company.)

## 2. Honorary Prof. Rajata Rajatanavin Age 75 Years



**Independent Director**

**Chairman of the Audit Committee**

**Shareholding Proportion: (As of Dec 31, 2025)**

- direct 0.06%
- indirect -None-

**Family relationship between executives: - None -**

**Duration of Directorship : 5 Years (10 Mar 2021 – Present)**

### Educational qualifications

- Advanced Diploma in Internal Medicine, Mahidol University
- Master's Degree in Medicine, Mahidol University
- Bachelor's Degree in Medical Science, Mahidol University
- Medical Professional Certification in Internal Medicine, Medical Council of Thailand
- Certificate of Expertise in Family Medicine, The Royal College of Family Physicians of Thailand
- Certificate of Expertise in Endocrinology and Metabolism, The Royal College of Physicians of Thailand
- Certificate of Fellowship Training Endocrinology & Metabolism University of Massachusetts Medical School

### Director training history

- Director Certification Program (DCP) Class 182, 2021

### work experience

#### **Listed Company : (1 EA.)**

- 2021 – Present      Independent Director      Bioscience Animal Health Public Company Limited  
Chairman of the Audit Committee

#### **Other companies (2 EA.)**

- 2023 – Present      Acting Deputy Secretary-Genera      Chulabhorn Royal Academy
- 2015 – Present      Director      Thep tanyapa Co., Ltd.

<b>- Current position</b>	Independent Director
<b>- History of attending the meeting in 2025</b>	Annual General Meeting of Shareholders 1/1 time Board of Directors 4/5 times Audit Committee 3/4 times
<b>- History of illegal acts in the past 10 years</b>	-None-
<b>- Qualification according to the laws and Does not have prohibited qualification according to the announcement of the SET</b>	Yes
<b>- Direct or indirect interest in any business in which the company is a party.</b>	-None-

(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

**3. Assoc. Prof. Dr. Jade Donovanik Age 53 Years**



**Independent Director**

**Audit Committee**

**Shareholding Proportion (As of Dec 31, 2025)**

- direct - None -

- indirect -None-

**Family relationship between executives: - None -**

**Duration of Directorship : 5 Years (10 Mar 2021 – Present)**

**Educational qualifications**

- Doctor of Juridical Science, Stanford University
- Master of Juridical Science, Stanford University
- Bachelor of Laws, Thammasat University

**Director training history**

- Director Certification Program (DCP) Class 127, 2016
- Directors Accreditation Program (DAP)

**work experience**

**Listed Company : (3 EA.)**

- |  |   |   |
|--|---|---|
| <ul style="list-style-type: none"> <li>● 2021 – Present</li> <li>● 2021 – Present</li> <li>● 2015 – Present</li> </ul> | <ul style="list-style-type: none"> <li>Independent Director</li> <li>Audit Committee</li> <li>Independent Director</li> <li>Independent Director</li> <li>Audit Committee</li> <li>Nomination Committee Member</li> <li>Risk Management Committee Member</li> </ul> | <ul style="list-style-type: none"> <li>Bioscience Animal Health Public Company Limited</li> <li>Deestone Corporation Public Company Limited</li> <li>Samittha Thang Gas Public Company Limited</li> </ul> |
|--|---|---|


**Other companies (8 EA.)**

- |                  |                                |   |
|------------------|--------------------------------|---|
| ● 2002 – Present | Chairman of the Board          | Law Office Co., Ltd.  |
| ● 2017 – Present | Chairman of the Faculty of Law | College of Asian Scholars   |
| ● 2014 – Present | Legal Advisor                  | Raus & Co. International (Thailand) Co., Ltd.                                     |
| ● 2014 – Present | Director                       | Enuwa Co., Ltd.   |
| ● 2014 – Present | Director                       | Research X Co., Ltd.  |
| ● 2008 – Present | Director                       | Jirada Co., Ltd.  |
| ● 2007 – Present | Legal Advisor                  | Kamthorn Surachet & Somsak Co., Ltd.  |
| ● 2002 – Present | Intellectual Property Advisor  | Department of Agricultural Extension, Ministry of<br>Agriculture and Cooperatives |

- |  |  |
|--|--|
| <b>- Current position</b>  | Independent Director   |
| <b>- History of attending the meeting in 2025</b>  | Annual General Meeting of Shareholders 1/1 time<br>Board of Directors 5/5 times<br>Audit Committee 4/4 times |
| <b>- History of illegal acts in the past 10 years</b>  | -None-   |
| <b>- Qualification according to the laws and<br/>Does not have prohibited qualification<br/>according to the announcement of the<br/>SET</b> | Yes  |
| <b>- Direct or indirect interest in any business<br/>in which the company is a party.</b>  | -None-   |


(The nominating director is not director or executive in other companies that may be conflict of interest with the Company and is an independent director who can give opinions independently and in accordance with relevant criteria.)

## Profiles of independent directors nominated by the Company as proxies for shareholders

Name	Age (year)	Position	Address	Conflict of interest in the proposed agenda
Mr. Thaweesak Songserm  	61	Member of the Audit Committee / Independent Director	63/1 Moo 10, Kamphaeng Saen, Kamphaeng Saen, Nakhon Pathom, postal code 73140	-None-

Special benefit extra from other Directors in this meeting: -None-

**Remark:** Profiles of Independent Directors are described in the 56-1 One report (Attachment 1)



Proxy Form A.

(General form which is simple and uncomplicated)

Written at.....

Date.....Month..... Year.....

(1) I..... Nationality.....

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code.....

(2) As a shareholder of Bioscience Animal Health Public Company Limited holding total of shares..... shares and having the right to vote equal to..... voted

(3) Hereby authorize

(1) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code. .... or

(2) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code ..... or

(3) Name..... age ..... year

Residing at No..... Road..... Tambol/Sub-district.....

Ampur/District..... Province..... Postal Code ..... or

Only one person as my representative to attend and vote on my behalf at the Annual General Meeting of Shareholders Wednesday, April 22, 2026 at 9:30 a.m. via electronic media (E-AGM).

Any business performed by the proxy in that meeting shall be regarded as if I had done it myself in all respects.

Signed.....Proxy Grantor Signed .....Proxy Holder

(.....)

(.....)

Signed..... Proxy Holder Signed .....Proxy Holder

(.....)

(.....)

Remark

Shareholders who appoint proxies must authorize only one proxy to attend and vote at the meeting, the number of shares cannot be divided among several proxies to split their votes.



หนังสือมอบฉันทะ (แบบ ข)

Proxy Form (Form B)

เขียนที่ .....

Written at

วันที่ ..... เดือน ..... พ.ศ. ....

Date Month Year

(1) ข้าพเจ้า ..... อายุ ..... ปี สัญชาติ..... I/

We age years, nationality

อยู่บ้านเลขที่.....

Residing at

ถนน ..... ตำบล/แขวง ..... อำเภอ/เขต .....

Road Tambol/Khwaeng Amphur/Khet

จังหวัด ..... รหัสไปรษณีย์.....

Province Postal Code

(2) เป็นผู้ถือหุ้นของ บริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน) (“บริษัท”)

being a shareholder of Bioscience Animal Health Public Company Limited (“The Company”)

โดยถือหุ้นจำนวนทั้งสิ้นรวม ..... หุ้น และออกเสียงลงคะแนนได้เท่ากับ..... เสียง ดังนี้

holding the total number of shares .....and having the right to vote equivalent to votes as follows:

หุ้นสามัญ ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Ordinary share of ...shares having the right to vote equivalent to .....votes

หุ้นบุริมสิทธิ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Preferred share of ....shares having the right to vote equivalent to .....votes

(3) ขอมอบฉันทะให้ประธานกรรมการตรวจสอบและกรรมการอิสระ

I hereby authorize the Chairman of the Audit Committee and Independent Director

ชื่อ นายทวีศักดิ์ สงเสริม อายุ 61 ปี อยู่บ้านเลขที่ 63/1 หมู่ 10  
 Name Mr. Thaweesak Songserm age 61 years, residing at 63/1 Moo 10  
 ถนน ตำบล กำแพงแสน อำเภอ กำแพงแสน จังหวัด นครปฐม  
 Road - Subdistrict Kamphaeng Saen District Kamphaeng Saen Province Nakhon Pathom  
 รหัสไปรษณีย์ 73140 หรือ  
 Postal Code 73140 or

ชื่อ ..... อายุ ..... ปี อยู่บ้านเลขที่ .....  
 Name age years, residing at  
 ถนน ตำบล/แขวง อำเภอ/เขต .....  
 Road Tambol/Khwaeng Amphur/Khet  
 จังหวัด รหัสไปรษณีย์ หรือ  
 Province Postal Code or

คนใดคนหนึ่งเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุม  
 สามัญผู้ถือหุ้นประจำปี 2569 ในวันพุธที่ 22 เมษายน 2569 เวลา 9.30 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

Be my representative to attend the meeting and vote on my behalf at the 2026 Annual General Meeting  
 of Shareholders on Wednesday, April 22, 2026 at 9:30 a.m. via electronic media (E-AGM).

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้

I / We hereby appoint the proxy to vote for me / us in this meeting as follows:

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be  
 deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

วาระที่ 1 พิจารณารับรองรายงานการประชุมสามัญผู้ถือหุ้น ประจำปี 2568

Agenda 1 To consider and approve the meeting minutes of the 2025 Annual General Meeting of  
 Shareholders

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

## วาระที่ 2 พิจารณารับทราบผลการดำเนินงานของบริษัท ในรอบปี 2568

Agenda 2 To consider and acknowledge the Company's operating performance for the year 2025

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

## วาระที่ 3 พิจารณานุมัติงบแสดงฐานะทางการเงิน งบกำไรขาดทุนเบ็ดเสร็จ และงบกระแสเงินสด สำหรับปีสิ้นสุด วันที่ 31 ธันวาคม 2568

Agenda 3 To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2025

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 4 พิจารณาอนุมัติการจ่ายเงินปันผล และตั้งสำรองตามกฎหมายประจำปี 2568**

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2025**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย                       ไม่เห็นด้วย                       งดออกเสียง  
Approve                              Disapprove                              Abstain

**วาระที่ 5 พิจารณาอนุมัติแต่งตั้งกรรมการแทนกรรมการที่ต้องออกตามวาระ**

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

การแต่งตั้งกรรมการทั้งหมด

Appointment of the whole group of directors

เห็นด้วย                       ไม่เห็นด้วย                       งดออกเสียง  
Approve                              Disapprove                              Abstain

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of an individual director

1. นายธนวัฒน์ คงเจริญสมบัติ                      Mr. Dhanawat Khongjaroensombat

เห็นด้วย                       ไม่เห็นด้วย                       งดออกเสียง  
Approve                              Disapprove                              Abstain

2. นายรัชตะ รัชตะนาวิน                      Mr. Rajata Rajatanavin

เห็นด้วย                       ไม่เห็นด้วย                       งดออกเสียง  
Approve                              Disapprove                              Abstain

3. นายเจษฎ์ โทณะวณิก

Mr. Jade Donovanik

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 6 พิจารณานุมัติค่าตอบแทนของกรรมการ ประจำปี 2569**

**Agenda 6 To consider and approve the directors' remuneration for the year 2026**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 7 พิจารณาแต่งตั้งผู้สอบบัญชี และกำหนดค่าสอบบัญชีประจำปี 2569**

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2026**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 8 พิจารณาเรื่องอื่นๆ (ถ้ามี)**

**Agenda 8 Consider other issues (if any)**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือฉันทะนี้ ให้ถือว่าการลงคะแนนเสียงนั้น ไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of proxy holder in any agendas which are not specified in this proxy shall be considered as invalid and not my voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้ หรือระบุไว้ไม่ชัดเจน หรือในกรณีที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใด ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we have not specified my/our voting intention in any agendas or unclearly specified or in case the meeting considers or passes resolutions in any matters other than those specified above, including in case there is any amendments or additions of any facts, the proxy shall have the right to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

**กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุมนั้น ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ**

Any acts performed by the proxy in this meeting shall be deemed to be the actions performed by myself/ourselves.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)

**หมายเหตุ/ Remark**

1. ผู้ถือหุ้นที่มอบฉันทะจะต้องให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุมและออกเสียงลงคะแนน ไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนเสียงได้

The shareholder appointing the proxy must authorize only one proxy to attend and vote at the meeting and may not split the number of shares to many proxies for splitting votes.

2. ผู้ถือหุ้นจะมอบฉันทะเท่ากับจำนวนหุ้นที่ระบุไว้ในข้อ (2) โดยไม่สามารถจะมอบฉันทะเพียงบางส่วนน้อยกว่าจำนวนที่ระบุไว้ในข้อ (2) ได้

The shareholder may grant the power to the proxy for all of the shares specified in Clause (2) and may not grant only a portion of the shares less than those specified in Clause (2) to the proxy.

3. ในกรณีที่มิวาระที่จะพิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ข) ตามแนบ

In case that any further agendas apart from specified above brought into consideration in the meeting, the proxy can state other agenda by using the Supplemental Proxy (Form B) as attached.

ใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ข)

Supplemental Proxy Form (Form B)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)

The proxy is granted by a shareholder of Bioscience Animal Health Public Company Limited.

ในการประชุมสามัญผู้ถือหุ้นประจำปี 2569 ในวันพุธที่ 22 เมษายน 2569 เวลา 9.30 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

At the 2026 Annual General Meeting of Shareholders on Wednesday, April 22, 2026 at 9:30 a.m. via electronic media (E-AGM).

\*\*\*\*\*

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

ข้าพเจ้าขอรับรองว่า รายการในใบประจำต่อหนังสือมอบฉันทะถูกต้องบริบูรณ์และเป็นความจริงทุกประการ  
I/We certify that the statements in this Supplemental Proxy Form are correct, completed and true in all respects.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor

(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy

(.....)



หนังสือมอบฉันทะ (แบบ ค)

Proxy (Form C)

(แบบที่ใช้เฉพาะกรณีผู้ถือหุ้นเป็นผู้ลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียน (Custodian) ในประเทศไทยเป็นผู้รับฝากและดูแลหุ้น) / Proxy Form C. (For foreign shareholders who have custodians in Thailand only)

เขียนที่ .....

Written at

วันที่ ..... เดือน ..... พ.ศ. ....

Date                      Month                      Year

(1) ข้าพเจ้า ..... สัญชาติ.....

I/ We ..... nationality

สำนักงานตั้งอยู่เลขที่.....

residing at

ในฐานะผู้ประกอบธุรกิจเป็นผู้รับฝากและดูแลหุ้น (Custodian) ให้กับ.....

Authorized Custodian of

(2) เป็นผู้ถือหุ้นของ บริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน) (“บริษัท”)

being a shareholder of Bioscience Animal Health Public Company Limited (“The Company”)

โดยถือหุ้นจำนวนทั้งสิ้นรวม ..... หุ้น และออกเสียงลงคะแนนได้เท่ากับ..... เสียง ดังนี้

holding the total amount of ..... shares and having the right to vote equals to ..... votes as follows:

หุ้นสามัญ ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Ordinary share ..... shares and having the right to vote equals to ..... votes

หุ้นบุริมสิทธิ..... หุ้น ออกเสียงลงคะแนนได้เท่ากับ ..... เสียง

Preference share ..... shares and having the right to vote equals to ..... votes

(3) ขอมอบฉันทะให้ (ผู้ถือหุ้นสามารถมอบฉันทะให้กรรมการอิสระของบริษัทก็ได้ โดยมีรายละเอียดตาม **สิ่งที่ส่งมาด้วยลำดับที่ 4**)

Hereby appoint to (The shareholder may appoint an independent director of the Company to be the proxy, per details as shown in the **Enclosure 4**)

ชื่อ นายทวีศักดิ์ ส่งเสริม อายุ 61 ปี อยู่บ้านเลขที่ 63/1 หมู่ 10  
 Name Mr. Thaweesak Songserm age 61 years, residing at 63/1 Moo 10  
 ถนน ตำบล กำแพงแสน อำเภอ กำแพงแสน จังหวัด นครปฐม  
 Road - Subdistrict Kamphaeng Saen District Kamphaeng Saen Province Nakhon Pathom  
 รหัสไปรษณีย์ 73140 หรือ  
 Postal Code 73140 or

ชื่อ ..... อายุ ..... ปี อยู่บ้านเลขที่ .....  
 Name ..... age ..... years, residing at .....  
 ถนน ตำบล/แขวง อำเภอ/เขต .....  
 Road Tambol/Khwaeng Amphur/Khet  
 จังหวัด ..... รหัสไปรษณีย์ .....  
 Province Postal Code or

คนใดคนหนึ่งเป็นผู้แทนของข้าพเจ้า เพื่อเข้าร่วมประชุมและออกเสียงลงคะแนนแทนข้าพเจ้า ในการประชุม  
 สัมภาษณ์ผู้ถือหุ้นประจำปี 2569 ในวันพุธที่ 22 เมษายน 2569 เวลา 9.30 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

Be my representative to attend the meeting and vote on my behalf at the 2026 Annual General Meeting  
 of Shareholders on **Wednesday, April 22, 2026 at 9:30 a.m.** via electronic media (E-AGM).

(4) ข้าพเจ้าขอมอบฉันทะให้ผู้รับมอบฉันทะออกเสียงลงคะแนนแทนข้าพเจ้าในการประชุมครั้งนี้ ดังนี้  
 I / We hereby appoint the proxy to vote for me / us in this meeting as follows:

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร  
 (a) The proxy shall consider and vote on behalf of myself / ourselves as it may be  
 deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้  
 (b) The proxy shall vote for me / us in accordance with my / our intention as follows:

**วาระที่ 1 พิจารณารับรองรายงานการประชุมสามัญผู้ถือหุ้น ประจำปี 2568**

**Agenda 1 To consider and approve the meeting minutes of the 2025 Annual General Meeting of Shareholders**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 2 พิจารณารับทราบผลการดำเนินงานของบริษัท ในรอบปี 2568**

**Agenda 2 To consider and acknowledge the Company's operating performance for the year 2025**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 3 พิจารณานุมัติงบแสดงฐานะทางการเงิน งบกำไรขาดทุนเบ็ดเสร็จ และงบกระแสเงินสด สำหรับปีสิ้นสุด วันที่ 31 ธันวาคม 2568**

**Agenda 3 To consider and approve the statements of financial position, the statements of comprehensive income and cash flows for the year ended at December 31, 2025**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 4 พิจารณานุมัติการจ่ายเงินปันผล และตั้งสำรองตามกฎหมายประจำปี 2568**

**Agenda 4 To consider and approve the dividend payment and set aside legal reserves for the year 2025**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

**วาระที่ 5 พิจารณานุมัติแต่งตั้งกรรมการแทนกรรมการที่ต้องออกตามวาระ**

**Agenda 5 To consider and approve the appointment of directors to replace those who retired by rotation**

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

การแต่งตั้งกรรมการทั้งหมด

Appointment of the whole group of directors

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

การแต่งตั้งกรรมการเป็นรายบุคคล

Appointment of an individual director

1. นายธนวัฒน์ คงเจริญสมบัติ

Mr. Dhanawat Khongjaroensombat

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

2. นายรัชตะ รัชตะนาวิน

Mr. Rajata Rajatanavin

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

3. นายเจษฎ์ โทณะวณิก Mr. Jade Donovanik
- เห็นด้วย  ไม่เห็นด้วย  งดออกเสียง
- Approve Disapprove Abstain

**วาระที่ 6 พิจารณานุมัติค่าตอบแทนของกรรมการ ประจำปี 2569**

**Agenda 6 To consider and approve the directors' remuneration for the year 2026**

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้
- (b) The proxy shall vote for me / us in accordance with my / our intention as follows:
- เห็นด้วย  ไม่เห็นด้วย  งดออกเสียง
- Approve Disapprove Abstain

**วาระที่ 7 พิจารณาแต่งตั้งผู้สอบบัญชี และกำหนดค่าสอบบัญชีประจำปี 2569**

**Agenda 7 To consider the appointment of the auditor and determine the audit fee for the year 2026**

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้
- (b) The proxy shall vote for me / us in accordance with my / our intention as follows:
- เห็นด้วย  ไม่เห็นด้วย  งดออกเสียง
- Approve Disapprove Abstain

**วาระที่ 8 พิจารณาเรื่องอื่น ๆ (ถ้ามี)**

**Agenda 8 Consider other issues (if any)**

- (ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร
- (a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.
- (ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้
- (b) The proxy shall vote for me / us in accordance with my / our intention as follows:
- เห็นด้วย  ไม่เห็นด้วย  งดออกเสียง
- Approve Disapprove Abstain

(5) การลงคะแนนเสียงของผู้รับมอบฉันทะในวาระใดที่ไม่เป็นไปตามที่ระบุไว้ในหนังสือฉันทะนี้ ให้ถือว่าการลงคะแนนเสียงนั้น ไม่ถูกต้องและไม่ใช่เป็นการลงคะแนนเสียงของข้าพเจ้าในฐานะผู้ถือหุ้น

Voting of proxy holder in any agendas which are not specified in this proxy shall be considered as invalid and not my voting as a shareholder.

(6) ในกรณีที่ข้าพเจ้าไม่ได้ระบุความประสงค์ในการออกเสียงลงคะแนนในวาระใดไว้ หรือระบุไว้ไม่ชัดเจน หรือในกรณีที่ประชุมมีการพิจารณาหรือลงมติในเรื่องใดนอกเหนือจากเรื่องที่ระบุไว้ข้างต้น รวมถึงกรณีที่มีการแก้ไขเปลี่ยนแปลงหรือเพิ่มเติมข้อเท็จจริงประการใด ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

In case I/we have not specified my/our voting intention in any agendas or unclearly specified or in case the meeting considers or passes resolutions in any matters other than those specified above, including in case there is any amendments or additions of any facts, the proxy shall have the right to consider and vote on my/our behalf as he/she may deem appropriate in all respects.

กิจการใดที่ผู้รับมอบฉันทะได้กระทำไปในการประชุมนั้น ให้ถือเสมือนว่าข้าพเจ้าได้กระทำเองทุกประการ

Any acts performed by the proxy in this meeting shall be deemed to be the actions performed by myself/ourselves.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

**หมายเหตุ/ Remark**

1. หนังสือมอบฉันทะแบบ ค. นี้ใช้เฉพาะกรณีที่ผู้ถือหุ้นที่ปรากฏชื่อในทะเบียนเป็นผู้ลงทุนต่างประเทศและแต่งตั้งให้คัสโตเดียน (Custodian) ในประเทศไทยเป็นผู้รับฝากและดูแลหุ้นให้เท่านั้น  
Only foreign shareholders whose names appear in the registration book and have appointed a Custodian in Thailand can use the Proxy Form C.
2. หลักฐานที่ต้องแนบพร้อมหนังสือมอบฉันทะคือ  
Evidence to be attached with this Proxy Form are:
  - (1) หนังสือมอบอำนาจจากผู้ถือหุ้นให้คัสโตเดียน (Custodian) เป็นผู้ดำเนินการลงนามในหนังสือมอบฉันทะแทน  
Power of Attorney from the shareholder authorizing a Custodian to sign the Proxy Form on behalf of the shareholder.
  - (2) หนังสือยืนยันว่าผู้ลงนามในหนังสือมอบได้รับอนุญาตประกอบธุรกิจฉันทะคัสโตเดียน (Custodian) Letter of certification to certify that a person executing the Proxy Form has obtained a permit to act as a Custodian.
3. ผู้ถือหุ้นที่มอบฉันทะจะต้องมอบฉันทะให้ผู้รับมอบฉันทะเพียงรายเดียวเป็นผู้เข้าประชุม และออกเสียงลงคะแนนไม่สามารถแบ่งแยกจำนวนหุ้นให้ผู้รับมอบฉันทะหลายคนเพื่อแยกการลงคะแนนได้  
The shareholder appoint the proxy must authorize only one proxy to attend and vote at the meeting and may not split the number of shares to several proxies for splitting votes
4. วาระแต่งตั้งกรรมการสามารถแต่งตั้งกรรมการทั้งชุดหรือแต่งตั้งกรรมการรายบุคคล  
In respect of the agenda as to the election of the directors, either the whole set of the nominated candidates or an individual nominee may be voted for
5. ในกรณีที่มีวาระที่พิจารณาในการประชุมมากกว่าวาระที่ระบุไว้ข้างต้น ผู้มอบฉันทะสามารถระบุเพิ่มเติมได้ในใบประจำต่อแบบหนังสือมอบฉันทะแบบ ค. ตามแนบ  
In the case where there are any further agenda apart from those specified above brought into consideration in the meeting, the Grantor may use the Allege of the Proxy Form C. as attached

ใบประจำต่อแบบหนังสือมอบฉันทะ (แบบ ค)

Supplemental Proxy (Form C)

การมอบฉันทะในฐานะเป็นผู้ถือหุ้นของบริษัท ไบโอสายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)

The proxy is granted by a shareholder of Bioscience Animal Health Public Company Limited.

ในการประชุมสามัญผู้ถือหุ้นประจำปี 2569 ในวันพุธที่ 22 เมษายน 2569 เวลา 9.30 น. ผ่านสื่ออิเล็กทรอนิกส์ (E-AGM)

At the 2026 Annual General Meeting of Shareholders on Wednesday, April 22, 2026 at 9:30 a.m. via electronic media (E-AGM).

\*\*\*\*\*

วาระที่..... เรื่อง.....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

ไม่เห็นด้วย

งดออกเสียง

Approve

Disapprove

Abstain

วาระที่..... เรื่อง .....

Agenda No..... Subject : .....

(ก) ให้ผู้รับมอบฉันทะมีสิทธิพิจารณาและลงมติแทนข้าพเจ้าได้ทุกประการตามที่เห็นสมควร

(a) The proxy shall consider and vote on behalf of myself / ourselves as it may be deemed appropriate in all respects.

(ข) ให้ผู้รับมอบฉันทะออกเสียงลงคะแนนตามความประสงค์ของข้าพเจ้า ดังนี้

(b) The proxy shall vote for me / us in accordance with my / our intention as follows:

เห็นด้วย

Approve

ไม่เห็นด้วย

Disapprove

งดออกเสียง

Abstain

ข้าพเจ้าขอรับรองว่า รายการในใบประจำต่อหนังสือมอบฉันทะถูกต้องบริบูรณ์และเป็นความจริงทุกประการ I/We certify that the statements in this Supplemental Proxy Form are correct, completed and true in all respects.

ลงนาม/Signed ..... ผู้มอบฉันทะ/Grantor  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

ลงนาม/Signed ..... ผู้รับมอบฉันทะ/Proxy  
(.....)

**Principle 8****Encourage participation and communication with shareholders.**

The Board of Directors recognizes and places importance on the basic rights of shareholders, both as investors in securities and group owners, such as the right to buy, sell, transfer the securities they hold the right to receive profit sharing from the group of companies; the right to obtain sufficient information; The right to attend meetings to exercise voting rights at the shareholders' meeting to appoint or remove directors, appoint an auditor Approval of important transactions that affect the business direction of the Group and matters affecting the group of companies such as the allocation of dividends Prescribing or amending the Memorandum of Association and Articles of Association of the Group capital reduction or capital increase and approval of special items, etc.

In this regard, the Group has a mission to promote and facilitate the exercise of shareholders' rights as follows:

- (1) Information on date, time, place and agenda of the meeting is provided. With explanations and reasons supporting each agenda or supporting the requested resolution as specified in the notice of the Annual General Meeting of Shareholders and the Extraordinary General Meeting of Shareholders. Or in the documents attached to the meeting agenda completely sufficient for the shareholders' decision. and refrain from any action that limits the opportunity for shareholders to study the information of the Group.
- (2) Facilitate all groups of shareholders to fully exercise their rights to attend and vote at the meeting and refrain from Any action that limits the opportunity of shareholders to attend the meeting, such as using a place that is convenient for traveling a map showing the meeting venue will be attached in the invitation letter. Including choosing the right day and time and allocate sufficient time for the meeting. Including attending the meeting to vote should not be complicated or too costly.
- (3) before the date of the shareholders' meeting The Group of Companies will allow shareholders to submit comments, suggestions or inquiries prior to the meeting date. The criteria for sending questions in advance are clearly defined. And notify the shareholders together with the delivery of the invitation letter to the shareholders' meeting. And the Group will publish such guidelines through the Group's website.

- (4) Encourage shareholders to use proxy forms in which they can determine their voting direction. and nominate at least one independent director as an alternative for proxy of shareholders.
- (5) in the shareholders' meeting the chairman of the meeting will allocate appropriate time and the group of companies will allow shareholders to have the opportunity to express their opinions. Suggestions or questions related to any agenda freely before voting on any agenda.
- (6) Encourage all directors and senior executives of the Group to attend the shareholders' meeting to answer shareholders' questions.
- (7) Arrange for the resolution of the shareholders' meeting for each item in the event that the agenda contains several items, such as the agenda for the appointment of Company Directors.
- (8) The Group will support the use of ballots for important agenda items such as connected transactions. transaction of acquisition or disposition of assets, etc. for transparency and accountability in counting the voting results.
- (9) The Group will arrange for an independent person to assist in the counting or checking of votes for each agenda. And disclosed to the meeting and recorded in the minutes of the meeting.
- (10) after the shareholders' meeting is completed, The Group will prepare minutes of meetings that accurately and completely record all important information. Important questions, opinions and suggestions will be recorded in the minutes of the meeting. for shareholders to be able to inspect. The minutes of the meeting were also published on the Group's website for shareholders to consider.
- (11) The Group will send a copy of the minutes of the shareholders' meeting to the SET within 14 days from the date of the shareholders' meeting.
- (12) Encourage the group companies to use technology in the shareholders' meeting. both registration of shareholders Score counting and display So that the conduct of the meeting can be done quickly, accurately and accurately.

In addition, the Board of Directors has prescribed the equitable treatment of all shareholders. Whether it is a major shareholder or a minor shareholder. Executive shareholders or non-executive shareholders Thai or foreign shareholders with the following guidelines:

- (1) Sending a meeting invitation letter with the agenda and opinions of the Board of Directors to the Stock Exchange of Thailand and disseminate the aforementioned meeting schedule through the Group's website in accordance with the rules, regulations and other relevant laws.
- (2) Determine criteria and procedures for minority shareholders to nominate candidates for the Company's directorship. Nominations can be made through the Nomination and Remuneration Committee in advance before the shareholders' meeting date. along with disseminating information for consideration of qualifications and consent of nominees.
- (3) Determine the criteria for minority shareholders to propose additional meeting agenda prior to the meeting date clearly in advance. To demonstrate fairness and transparency in considering whether to add an agenda proposed by minority shareholders or not.
- (4) Executive shareholders should not unnecessarily add to the agenda without notice in advance. Especially important agenda that shareholders must take time to study the information before making a decision.
- (5) In conducting each shareholder meeting The company will give equal opportunities to all shareholders. before the start of the meeting the chairman of the meeting will explain to the shareholders the rules and regulations used in the meeting. How to exercise your voting rights Voting rights according to each type of share and how to count the votes of shareholders who have to vote for each agenda.
- (6) In the agenda for the election of company directors The Group will support the election of individual directors.
- (7) Require company directors to report their interest in any meeting agenda at least before considering the relevant agenda in the Board of Directors' meeting and record such interest in the minutes of the Board of Directors' meeting. Including prohibiting company directors who have

significant interests in a manner that is unable to freely express opinions on related agendas from voting in the meeting on that agenda.

- (8) Establish written guidelines for safeguarding and preventing the use of internal information by the Group. And notify such guidelines to everyone in the group of companies to follow. All company directors and executives who have a duty to report their securities holdings according to the law are obligated to submit such reports to the company secretary. To present to the Board of Directors for acknowledgment in the next meeting and disclose in the annual report of the group of companies.



Personal Data Protection Notice (Privacy Notice) for Shareholders

QR Code for downloading the Personal Data Protection Notice (Privacy Notice) for the Annual General Meeting of Shareholders for the year 2026 of Bioscience Animal Health Public Company Limited



## Instructions and Guidelines for Attending the Shareholders' Meeting via Electronic Media (E-Meeting)

Shareholders or proxy holders who wish to attend the Meeting are required to submit the identification documents as specified to the Company or via the Company's website no later than 17 April 2026. In the case of registration via the website (<https://www.affinityrelation.com>), shareholders may register until the closing of the Meeting. Once the Company has verified the information against the list of shareholders entitled to attend the Meeting as of the record date, and the information is complete and accurate, the E-Meeting service provider will send the link for attending the Meeting, together with the user manual, to the email address provided to the Company. The link will be delivered 1–2 days prior to the Meeting date.

### Notification of Intention to Attend the Meeting via Electronic Media

Shareholders who wish to attend the meeting via electronic media must notify their intention through one of the following three methods:

1. Submission of the attendance confirmation form via email
2. Submission of the attendance confirmation form by post
3. Registration via the website: <https://www.affinityrelation.com/service/>



By selecting the Annual General Meeting of Shareholders of [Bioscience Animal Health Public Company Limited](#) and completing the registration process, including uploading the required documents as instructed in the system

### For Notification of Intention to Attend the Meeting via Electronic Media by Email or Postal Mail

1. Please complete the meeting attendance confirmation form for the electronic meeting (E-Meeting), ensuring that your email address and mobile phone number are clearly provided for registration purposes.
2. Attach identity verification documents as proof of your right to attend the E-Meeting.
  - 2.1. Individual Shareholders
    - 2.1.1. In case the shareholder wishes to attend the meeting via electronic media (E-Meeting) in person
      - 2.1.1.1. A copy of a valid government-issued identification document, such as a national ID card, government official ID card, driver's license, or passport. If there has been a change in name or surname, supporting documents must be attached.
    - 2.1.2. In case the shareholder appoints a proxy to attend the meeting via electronic media (E-Meeting) on their behalf
      - 2.1.2.1. Proxy Form A, B, or C (available for download at <https://investor.bis-group.com/>), duly completed and signed by both the grantor and the proxy, with the required stamp duty affixed.

2.1.2.2. A copy of a valid government-issued identification document of the shareholder (grantor), such as a national ID card, government official ID card, driver's license, or passport. If there has been a change in name or surname, supporting documents must be attached.

The shareholder (grantor) must sign and certify the copy as a true and correct document.

2.1.2.3. A copy of a valid government-issued identification document of the proxy, such as a national ID card, government official ID card, driver's license, or passport. If there has been a change in name or surname, supporting documents must be attached. The proxy must sign and certify the copy as a true and correct document.

## 2.2. Legal Entity

2.2.1. In the case where an authorized signatory (director) of the juristic person wishes to attend the meeting in person via electronic media:

2.2.1.1. A copy of the corporate shareholder's certificate of incorporation, issued no more than one year prior to the Annual General Meeting date, certified as a true copy by the authorized signatory (director) of the juristic person.

2.2.1.2. A copy of a valid government-issued identification document of the authorized signatory (director) of the juristic person, such as a national ID card, government officer card, driver's license, or passport. In the event of a name or surname change, supporting documents must be provided. All copies must be signed and certified as true copies.

2.2.2. In the case where a proxy is appointed to attend the meeting via electronic media:

2.2.2.1. Proxy Form A, B, or C (available for download at <https://investor.bis-group.com/>), duly completed and signed by both the grantor and the proxy, with the required stamp duty affixed.

2.2.2.2. A copy of the corporate shareholder's certificate of incorporation, issued no more than one year prior to the Annual General Meeting date, certified as a true copy by the authorized signatory (director) of the juristic person.

2.2.2.3. A copy of a valid government-issued identification document of the authorized signatory (director) of the juristic person, such as a national ID card, government officer card, driver's license, or passport. In the event of a name or surname change, supporting documents must be provided. All copies must be signed and certified as true copies.

2.2.2.4. A copy of a valid government-issued identification document of the proxy, as required for an individual, as mentioned above.

**Note:** If any of the above documents or evidence is not in Thai or English, the shareholder must provide an English translation, duly signed to certify its accuracy by the shareholder or an authorized signatory of the juristic person (in the case of a juristic person).

### Appointment of an Independent Director as Proxy

In the event that a shareholder wishes to appoint an Independent Director of the Company as proxy, details of the designated Independent Directors are provided in **Enclosure No. 4**. Such Independent Directors have no special interest in any agenda item proposed at this Meeting, except for Agenda Item 6 regarding the consideration and approval of directors' remuneration for the year 2026.

3. Register or send documents to notify your intention to attend the meeting via electronic media and proof of identity with other supporting documents by sending them to the company through the following channels:
  - E-mail: Chanika.k@bis-group.com (within April 17, 2026)
  - Postal Mail: Company Secretary and Investor Relations Department, Bioscience Animal Health Public Company Limited, No. 479, 4<sup>th</sup> Floor, Muangthongthani, Bondstreet Road, Bangphut, Pakkret, Nonthaburi 11120 (Documents must be received by April 17,2026)
  - Website: Submit documents via <https://www.affinityrelation.com/service/> (On April 22, 2026, registration will remain open until the Meeting is adjourned.)
  - For further inquiries, please contact the Company Secretary and Investor Relations Department, Bioscience Animal Health Public Company Limited at 02-9600290-5 ext. 501 and 085-1881392
  - In the event that participants encounter problems using the AFF E meeting, they can contact the company. Affinity Relations Co., Ltd. (Tel 099-2653563 or 087-6965439 or 061-7641234)

### Registration Process for Attending the Meeting via E-AGM AFF Online Service

1. Proceed with the registration to attend the meeting via the link provided by the company, access the website for registration, or scan the QR code below.

Via the website

<https://www.affinityrelation.com/service/>

Via QR Code



2. Select the Annual general shareholders' meeting of the company BIS that you will attend.
3. Complete the registration process on the website and upload a copy of the shareholder's identification card as required.
4. For proxy registration, the proxy form, along with copies of the identification cards of both the grantor and the proxy, must be uploaded into the system for verification.
5. Once the company has received the registration details and completed the verification process to confirm shareholder rights, an email containing the meeting access link will be sent to the email address provided in the registration form at least two business days before the meeting date.
6. On the meeting day, log in to the system using the shareholder account number (securities registration number) and the reference number (shareholder's identification card number).
7. Attendance will be counted toward the meeting quorum only if the shareholder logs in via the provided meeting system link on the meeting day. (Participation via Zoom meeting alone will not be considered as official attendance for quorum purposes.)

#### Attending the Meeting via Electronic Media E-AGM AFF Online Service through Zoom Meeting

1. Once the shareholder or proxy has successfully registered and submitted the required documents for attending the Annual General Meeting, and after the company has verified the information, the meeting organizer, on behalf of Affinity Relation Co., Ltd., will send an email containing the meeting access link to the email address provided during registration. This email will be sent at least two business days before the meeting date. Please carefully review the user manual for attending the meeting via electronic means. If you do not receive the email by April 23, 2025, please contact the company immediately using the previously provided contact details.
2. The electronic meeting and voting system can be accessed on all devices, including desktop computers, laptops, tablets, and mobile phones, through a web browser (Chrome).
3. For optimal streaming quality during the meeting, it is recommended to use a 4G network, broadband internet, or Wi-Fi connection.

4. As the E-Meeting system provided by Affinity Relation Co., Ltd. integrates with Zoom Meeting, shareholders who have never used Zoom before or have not yet installed the Zoom application on their devices may download and install it using the links provided below.

iOS	Android
	
<a href="https://apps.apple.com/th/app/zoom-cloud-meetings/id546505307">https://apps.apple.com/th/app/zoom-cloud-meetings/id546505307</a>	<a href="https://play.google.com/store/apps/details?id=us.zoom.videomeetings">https://play.google.com/store/apps/details?id=us.zoom.videomeetings</a>

5. The system will be open for access 1 hour (60 minutes) before the meeting starts. However, the live broadcast of the meeting will only begin at the scheduled meeting time.
6. To log in to the system, participants must use their shareholder account number (securities registration number) and reference number (shareholder's identification card number). Shareholders must log in via the link sent to their registered email only. The provided link cannot be shared or used by another shareholder to log in with a different account.
7. Voting via the E-AGM AFF Online Service allows shareholders to cast their votes for each agenda item by selecting "Approve," "Disapprove," or "Abstain." If no vote is cast for a particular agenda item, the system will automatically consider it as an "Approve" vote (vote counting will be based on transferring the uncast votes to the approval count).
8. If participants encounter technical issues or difficulties while using the E-AGM AFF Online Service, they may contact Affinity Relation Co., Ltd. at: Phone: 099-265-3563, 096-812-5545, or 087-696-5429

**ใบตอบรับเข้าร่วมประชุมผ่านสื่ออิเล็กทรอนิกส์**  
**บริษัท ไบโอซายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)**  
**Electronic Meeting Attendance Confirmation Form**  
**Bioscience Animal Health Public Company Limited**

- (1) ข้าพเจ้า \_\_\_\_\_ สัญชาติ \_\_\_\_\_  
 I/We \_\_\_\_\_ Nationality  
 อยู่บ้านเลขที่ \_\_\_\_\_  
 Address \_\_\_\_\_
- (2) เป็นผู้ถือหุ้นของบริษัท ไบโอซายน์ แอนิมัล เฮลท์ จำกัด (มหาชน)  
 Being a shareholder of Bioscience Animal Health public company limited  
 โดยถือหุ้นจำนวนทั้งสิ้นรวม \_\_\_\_\_ หุ้น  
 Holding the total amount of \_\_\_\_\_ shares

ประสงค์จะเข้าร่วมประชุมและลงคะแนนผ่านสื่ออิเล็กทรอนิกส์ (E-AGM) สำหรับการประชุมสามัญผู้ถือหุ้นประจำปี 2569 โดย  
 ต้องการเข้าร่วมประชุม

Wish to attend and vote through electronic means (E-AGM) for the 2026 Annual General Meeting of Shareholders  
 with the intention of attending the meeting.

เข้าร่วมประชุมด้วยตัวเอง

Attend the meeting by yourself

มอบฉันทะให้ (นาย/นาง/นางสาว) \_\_\_\_\_

Attend the meeting by yourself \_\_\_\_\_

หมายเลขบัตรประชาชน \_\_\_\_\_ ได้เข้าร่วมประชุมดังกล่าวข้างต้น

ID card number \_\_\_\_\_ Attend the above meeting

- (3) ข้อมูลในการจัดส่งวิธีการเข้าร่วมประชุม  
 Delivery information, method of meeting attendance  
 อีเมล \_\_\_\_\_ (โปรดระบุ)  
 E-mail \_\_\_\_\_ (Please specify)  
 เบอร์โทร \_\_\_\_\_ (โปรดระบุ)  
 Phone Number \_\_\_\_\_ (Please specify)

- (4) จัดส่งเอกสารเพื่อยืนยันตัวตน วิธีการเข้าร่วมประชุม ภายในวันที่ 17 เมษายน 2569

Send documents for identity verification according, methods for attending the meeting by April 17, 2026.

- (5) เมื่อท่านได้รับการยืนยันตัวตนแล้ว บริษัทฯ จะจัดส่งลิงค์การเข้าร่วมประชุมและวิธีการเข้าร่วมประชุมไปยังอีเมลที่ท่านได้ระบุ

Once your identity has been verified, the company will send a link to attend the meeting and the method of meeting attendance to the email you specified.

- (6) ในวันประชุมผู้ถือหุ้นจะต้องเตรียม เลขบัญชีผู้ถือหุ้น และเลขบัตรประชาชนไว้ สำหรับการเข้าร่วมประชุมผ่านสื่ออิเล็กทรอนิกส์

On the day of Annual Ordinary General Meeting, prepare shareholder account number and the ID card number for attending the meeting via electronic media

หากท่านไม่สามารถเข้าร่วมประชุมผ่านสื่ออิเล็กทรอนิกส์ และประสงค์เข้าร่วมประชุมและออกเสียงลงคะแนนในการประชุมครั้งนี้ โปรด  
 กรอกรายละเอียดและลงนามในหนังสือมอบฉันทะ ปรากฏตามสิ่งที่ส่งมาด้วย และปิดอากรแสตมป์จำนวน 20 บาท พร้อมกับนำหนังสือมอบ  
 ฉันทะเอกสารหรือหลักฐานเพื่อแสดงตน และเอกสารประกอบในการเข้าร่วมประชุมโดยส่งให้แก่เจ้าหน้าที่ลงทะเบียนก่อนวันที่กำหนด และ  
 ในกรณีที่ท่านประสงค์จะมอบฉันทะให้กรรมการอิสระเป็นผู้เข้าร่วมประชุมแทน โปรดกรอกรายละเอียดและลงนามในหนังสือมอบฉันทะที่ส่ง  
 มาด้วย โดยท่านสามารถส่งหนังสือมอบฉันทะพร้อมเอกสารประกอบเพื่อแสดงตนมายังบริษัท ภายในวันที่ 17 เมษายน 2569

If you are unable to attend the meeting via electronic media and wish to attend and vote in this meeting. Please complete and  
 sign the proxy form. It appears as in the enclosure and affixed 20 baht stamp duty together with the proxy form, documents or  
 evidence for identification and supporting documents for attending the meeting, sent to the registration officer before the  
 specified date. And in the event that you wish to appoint an independent director to attend the meeting instead Please  
 complete and sign the proxy form provided. You can send the proxy form together with supporting documents for identification  
 to the company by April 17, 2026.